Study for the effect of visceral fat reduction by SGLT2 inhibitor Ipragliglozinin patients with type 2 diabetes

Study for the effect of visceral fat reduction by SGLT2 inhibitor Ipragliglozinin patients with type 2 diabetes - Visceral fat reduction by SGLT2 inhibitor Ipragliflozin

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000014058

Enrollment

Registered

2014-05-26

Start date

2014-05-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellitus

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) outpatients with type 2 diabetes who will start taking Ipragliflozin, 2) well-controlled in terms of blood pressure and lipids, 3) made a written informed consent

Exclusion criteria

Exclusion criteria: 1) hypersensitivity to Ipragliflozin, 2) unstable diabetic retinopathy, 3) severe hepatic, renal, or heart dysfunction, 4) pregnancy, 5) patients who are inadequate to enter this study due to the other reasons by physician's judgments

Design outcomes

Primary

Measure	Time frame
Change in visceral fat volume	—

Secondary

Measure	Time frame
1) glucose and lipid metabolism, 2) Abdominal circumference, 3) Weight, 4) Insulin secretion and insulin resistance, 5) microalbuminuria, 6) blood test(complete blood count, electrolytes, kidney and liver function test), 7) several biomarkers (adipokines, oxidative stress, etc)	—

Countries

Japan

Contacts

Public ContactHideaki Miyoshi

Hokkaido University Hospital Department of Internal Medicine II

hmiyoshi@med.hokudai.ac.jp011-706-5915

Outcome results